Cargando…
Antimicrobial peptides and the gut microbiome in inflammatory bowel disease
Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enter...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613745/ https://www.ncbi.nlm.nih.gov/pubmed/34887639 http://dx.doi.org/10.3748/wjg.v27.i43.7402 |
_version_ | 1784603700921106432 |
---|---|
author | Gubatan, John Holman, Derek R Puntasecca, Christopher J Polevoi, Danielle Rubin, Samuel JS Rogalla, Stephan |
author_facet | Gubatan, John Holman, Derek R Puntasecca, Christopher J Polevoi, Danielle Rubin, Samuel JS Rogalla, Stephan |
author_sort | Gubatan, John |
collection | PubMed |
description | Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD. |
format | Online Article Text |
id | pubmed-8613745 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-86137452021-12-08 Antimicrobial peptides and the gut microbiome in inflammatory bowel disease Gubatan, John Holman, Derek R Puntasecca, Christopher J Polevoi, Danielle Rubin, Samuel JS Rogalla, Stephan World J Gastroenterol Frontier Antimicrobial peptides (AMP) are highly diverse and dynamic molecules that are expressed by specific intestinal epithelial cells, Paneth cells, as well as immune cells in the gastrointestinal (GI) tract. They play critical roles in maintaining tolerance to gut microbiota and protecting against enteric infections. Given that disruptions in tolerance to commensal microbiota and loss of barrier function play major roles in the pathogenesis of inflammatory bowel disease (IBD) and converge on the function of AMP, the significance of AMP as potential biomarkers and novel therapeutic targets in IBD have been increasingly recognized in recent years. In this frontier article, we discuss the function and mechanisms of AMP in the GI tract, examine the interaction of AMP with the gut microbiome, explore the role of AMP in the pathogenesis of IBD, and review translational applications of AMP in patients with IBD. Baishideng Publishing Group Inc 2021-11-21 2021-11-21 /pmc/articles/PMC8613745/ /pubmed/34887639 http://dx.doi.org/10.3748/wjg.v27.i43.7402 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Frontier Gubatan, John Holman, Derek R Puntasecca, Christopher J Polevoi, Danielle Rubin, Samuel JS Rogalla, Stephan Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
title | Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
title_full | Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
title_fullStr | Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
title_full_unstemmed | Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
title_short | Antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
title_sort | antimicrobial peptides and the gut microbiome in inflammatory bowel disease |
topic | Frontier |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8613745/ https://www.ncbi.nlm.nih.gov/pubmed/34887639 http://dx.doi.org/10.3748/wjg.v27.i43.7402 |
work_keys_str_mv | AT gubatanjohn antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease AT holmanderekr antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease AT puntaseccachristopherj antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease AT polevoidanielle antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease AT rubinsamueljs antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease AT rogallastephan antimicrobialpeptidesandthegutmicrobiomeininflammatoryboweldisease |